Pfizer is focused on increasing treatment options for patients through research and development as well as innovative, technically advanced manufacturing practices. We’re proud to be strengthening our capacity to develop and produce more advanced medicines that can help improve the lives of patients. As part of that effort, we recently announced an $18 million expansion of Pfizer’s distribution center in Pleasant Prairie, Wisconsin.
Pfizer’s Pleasant Prairie facility is key to distributing Pfizer drugs around the world. When at capacity, the facility can store over 18 million vials at any given time. The facility also plays a major role in distributing the Pfizer-BioNTech COVID-19 vaccine, serving as the center for smaller shipments and vaccination kits. It is also the hub for international exports of the vaccine.
During its expansion, the Pleasant Prairie facility has created new jobs and in 2022, Pfizer hopes to employ over 180 persons at this facility. This investment supports both Wisconsin’s economy and patient access to the medicines they need. Our Ready for Cures community is dedicated to improving access to life-saving medicines and fostering a public policy environment that supports healthcare innovation. We believe harmful policies across the healthcare system are stifling the full potential of today’s scientific breakthroughs.
We need your support to show elected officials that it’s time to invest in research and innovation and remove barriers that continue to stand between access to life-saving medicines and the patients who need them the most.
The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at www.cvdvaccine.com.